At present, the domestic pharmaceutical field is facing major changes and reshuffles
.
In this context, many companies are also accelerating the expansion of product pipelines through acquisitions to enhance market competitiveness
.
Recently, Harbour Biomed announced that it will exclusively license its late-stage bartolimab (HBM9161) to Embip Pharmaceutical
, a subsidiary of CSPC Group.
It is understood that the bartolimab (HBM9161) authorized by Harbour Biopharma to CSPC is a fully human monoclonal antibody
that can selectively bind to and inhibit the FcRn receptor.
In 2017, Harbour BioMed licensed HanAll to introduce the rights to
develop, manufacture and commercialize the project in Greater China.
After 5 years of research by Harbour Biopharma, the drug has entered phase 3 clinical trials for systemic myasthenia gravis (gMG) and plans to submit a marketing application this year; Indications for thyroid eye disease (TED), neuromyelitis optica spectrum disease (NMOSD) and primary immune thrombocytopenia (ITP) have also progressed
.
In fact, for traditional pharmaceutical companies, the acquisition of new companies and products has long become one of
the ways to quickly replenish the pipeline.
In recent years, in order to comply with the development of the industry, CSPC Group has been continuously expanding and optimizing its own pipeline through independent research and development, acquisition, and stake in new companies
.
In fact, this is not the first time that CSPC has purchased domestic biotech products
.
It is reported that at the beginning of this year, CSPC Group announced that it had completed the acquisition of 100% of the interests of Zhuhai Zhifan Enterprise Management Consulting Center (Limited Partnership) (hereinafter referred to as "Zhuhai Zhifan") by an independent third party, and Zhuhai Zhifan held about 51%
of the registered capital of Guangzhou Wankang Bioengineering Co.
, Ltd.
(hereinafter referred to as "WINCOM Biotechnology").
According to the data, WINCOM Biologics is a biotechnology company
engaged in the research and development, production and sales of biological drugs.
At present, the company's independent research and development of Mingfule (recombinant human TNK tissue plasminogen activator for injection) is a third-generation specific thrombolytic drug with intellectual property rights, which has been marketed in China in 2015 for the treatment of thrombolysis in patients with acute myocardial infarction within 6 hours of onset; Its indication for thrombolysis of cerebral infarction was approved for clinical trial in 2017, and phase III clinical trial (TRACEII)
was launched in 2021.
It is reported that the current unit price of the drug is 4000-8000 yuan / box (1.
0*10E7IU/16mg).
In addition, in order to develop innovative drugs last year, CSPC also entered into a number of transactions with Kangnuoya, obtaining exclusive rights
to the anti-IL-4Rα monoclonal antibody CM310 and anti-TSLP recombinant humanized monoclonal antibody CM326 in China (excluding Hong Kong, Macao and Taiwan) for the treatment of respiratory diseases such as moderate to severe asthma and chronic obstructive pulmonary disease (COPD).
In addition, it also obtained the exclusive license of the third generation EGFR-TKI (BPI-7711 capsules) of Shanghai Beta Pharmaceutical through equity subscription.
.
.
In recent years, CSPC Group has mainly walked on two legs through self-research and introduction, and its innovative R&D pipeline has become increasingly rich
.
According to the Insight database, CSPC currently has a total of 80 innovative drugs under research
worldwide.
Among them, 6 models have been approved for marketing and 4 are in the process of being submitted for marketing, including JMT103, Irinotecan liposome, rezetinib and ripetunumab
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
